

Vik Khullar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4681975/publications.pdf>

Version: 2024-02-01

44
papers

1,629
citations

471509

17
h-index

289244

40
g-index

47
all docs

47
docs citations

47
times ranked

1307
citing authors

#	ARTICLE	IF	CITATIONS
1	Does cystoscopy method affect the investigation of bladder pain syndrome/interstitial cystitis?. International Urogynecology Journal, 2021, 32, 1229-1235.	1.4	3
2	Urogynaecology and Ehlersâ€“Danlos syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 579-585.	1.6	2
3	Posterior tibial nerve stimulation for overactive bladderâ€“techniques and efficacy. International Urogynecology Journal, 2020, 31, 865-870.	1.4	41
4	Does size matter? Perineometer and digital examination of a model levator hiatus. Neurourology and Urodynamics, 2020, 39, 1338-1344.	1.5	3
5	Interstitial cystitis/bladder pain syndrome and recurrent urinary tract infection and the potential role of the urinary microbiome. Post Reproductive Health, 2020, 26, 87-90.	0.9	13
6	The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?. International Urogynecology Journal, 2020, 31, 1387-1392.	1.4	11
7	Can we harness the placebo effect to improve care in lower urinary tract dysfunction? ICIâ€“RS 2019. Neurourology and Urodynamics, 2020, 39, S80-S87.	1.5	2
8	Abnormal vaginal microbiome associated with vaginal mesh complications. Neurourology and Urodynamics, 2019, 38, 2255-2263.	1.5	11
9	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICIâ€“RS 2018. Neurourology and Urodynamics, 2019, 38, S66-S70.	1.5	4
10	Midurethral slings for treatment of stress urinary incontinence review. Neurourology and Urodynamics, 2019, 38, S70-S75.	1.5	12
11	Recommendations and future research initiative to optimize bladder management in pregnancy and childbirth International Consultation on Incontinence â€“Research society 2018. Neurourology and Urodynamics, 2019, 38, S104-S110.	1.5	7
12	How can we improve the diagnosis and management of bladder pain syndrome? Part 2: ICIâ€“RS 2018. Neurourology and Urodynamics, 2019, 38, S71-S81.	1.5	8
13	Validation study of ultrasound bladder wall thickness measurements. International Urogynecology Journal, 2019, 30, 1575-1580.	1.4	6
14	The use of laser in urogynaecology. International Urogynecology Journal, 2019, 30, 683-692.	1.4	27
15	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. European Urology, 2019, 75, 129-168.	1.9	19
16	Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placeboâ€“controlled, doubleâ€“blind, parallel group study. Neurourology and Urodynamics, 2018, 37, 237-243.	1.5	7
17	Urodynamics are necessary for patients with asymptomatic pelvic organ prolapse. Neurourology and Urodynamics, 2018, 37, 2841-2846.	1.5	8
18	Current controversies in urinary tract infections: ICIâ€“RS 2017. Neurourology and Urodynamics, 2018, 37, S86-S92.	1.5	65

#	ARTICLE	IF	CITATIONS
19	Under what circumstances should stress incontinence surgery be performed at the same time as prolapse surgery? ICIâ€RS 2015. <i>Neurourology and Urodynamics</i> , 2017, 36, 909-914.	1.5	5
20	Personal goals and expectations of OAB patients in the UK. <i>Neurourology and Urodynamics</i> , 2017, 36, 1194-1200.	1.5	9
21	Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study. <i>Neurourology and Urodynamics</i> , 2016, 35, 819-825.	1.5	16
22	Patientâ€reported outcomes with the Î² 3 â€adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. <i>Neurourology and Urodynamics</i> , 2016, 35, 987-994.	1.5	23
23	Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. <i>Neurourology and Urodynamics</i> , 2015, 34, 438-443.	1.5	12
24	Emerging drugs for overactive bladder. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 613-624.	2.4	4
25	Efficacy of the Î²3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials. <i>European Urology</i> , 2015, 67, 11-14.	1.9	47
26	The relationship between BMI and urinary incontinence subgroups: Results from EpiLUTS. <i>Neurourology and Urodynamics</i> , 2014, 33, 392-399.	1.5	72
27	Clinical value of a patientâ€reported goalâ€attainment measure: the global development of selfâ€assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2014, 33, 90-94.	1.5	12
28	European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder. <i>International Urogynecology Journal</i> , 2013, 24, 1529-1536.	1.4	8
29	Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. <i>BMC Urology</i> , 2013, 13, 45.	1.4	56
30	Efficacy and Tolerability of Mirabegron, a Î²3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised Europeanâ€Australian Phase 3 Trial. <i>European Urology</i> , 2013, 63, 283-295.	1.9	370
31	Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder. <i>BJU International</i> , 2013, 112, 820-829.	2.5	10
32	Racial differences in female urethral morphology and levator hiatal dimensions: An ultrasound study. <i>Neurourology and Urodynamics</i> , 2012, 31, 502-507.	1.5	15
33	Intraobserver and interobserver reliability of the three-dimensional ultrasound imaging of female urethral sphincter using a translabial technique. <i>International Urogynecology Journal</i> , 2012, 23, 1063-1068.	1.4	18
34	Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?. <i>International Urogynecology Journal</i> , 2012, 23, 179-192.	1.4	17
35	Time-to-effect with darifenacin in overactive bladder: a pooled analysis. <i>International Urogynecology Journal</i> , 2011, 22, 1573-1580.	1.4	6
36	Female pelvic surgical devices and techniques need better evidenceâ€based medicine. <i>Neurourology and Urodynamics</i> , 2010, 29, 670-675.	1.5	2

#	ARTICLE	IF	CITATIONS
37	The effect of mode of delivery on pelvic floor functional anatomy. International Urogynecology Journal, 2008, 19, 407-416.	1.4	80
38	Fesoterodine Dose Response in Subjects With Overactive Bladder Syndrome. Urology, 2008, 71, 839-843.	1.0	96
39	Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse?. International Urogynecology Journal, 2007, 18, 1439-1443.	1.4	86
40	The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. Urology, 2006, 68, 38-48.	1.0	85
41	The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis. European Urology, 2005, 48, 5-26.	1.9	233
42	?Unblinding? in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. Neurourology and Urodynamics, 2005, 24, 13-20.	1.5	24
43	Pressure flow study: A useful diagnostic test of female lower urinary tract symptoms. Neurourology and Urodynamics, 2004, 23, 104-108.	1.5	29
44	Reproducibility and reliability of pressure flow parameters in women. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 774-776.	2.3	45